Company news
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) news
Oramed Pharmaceuticals Inc. news releases on 6ix. Latest, Apr 4, 2022: Oramed Appoints Yadin Rozov to its Board of Directors
Press releases — page 2
Oramed Appoints Yadin Rozov to its Board of Directors
April 3, 2022
Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians
March 28, 2022
Oramed to Host Key Opinion Leader Webinar on Need for Oral Insulin in Type 2 Diabetes
March 21, 2022
Oramed Completes Patient Enrollment in Phase 2 Oral Insulin NASH Trial
March 15, 2022
Oramed to Present at Barclays Global Healthcare Conference
March 9, 2022
Oramed Issues Annual Message to Shareholders
January 11, 2022
Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins
January 4, 2022
Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia
December 28, 2021
MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia
December 28, 2021
Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa
December 13, 2021
Oramed Pharmaceuticals Appoints Chief Legal Officer
December 7, 2021
Oramed to Join MSCI USA Small Cap Index
November 23, 2021
Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study
November 22, 2021
Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America
November 17, 2021
MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America
November 17, 2021
Oramed to Present at H.C. Wainwright 7th Annual Israel Conference
November 10, 2021
Oramed Announces Closing of $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
November 7, 2021
Oramed Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
November 2, 2021
Oramed Announces Oravax's Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial
October 28, 2021
Oramed to Present at Cantor Fitzgerald Virtual Global Healthcare Conference
September 22, 2021
Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment
September 14, 2021
Oramed to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 8, 2021
Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials
August 23, 2021
MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine
August 9, 2021
Oramed to Present at Canaccord Genuity's 41st Annual Growth Conference
August 8, 2021
Oravax to Present Keynote Talk on Oral COVID-19 Vaccine at the Arena International Vaccines Virtual Conference 2021
August 4, 2021
Oramed Pharmaceuticals Appoints Chief Commercial Officer
July 28, 2021
Oramed Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial
July 20, 2021
Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
June 21, 2021
Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study
June 7, 2021
Oramed Issues Letter to Shareholders with Updates on Oral Insulin and COVID-19 Vaccine
May 24, 2021
Oramed Pharmaceuticals and Oravax Medical to be Featured in Alliance Global Partners' Grand Rounds: A Webinar in Biotech and Specialty Pharma
April 20, 2021
Oramed Initiates Second Phase 3 Oral Insulin Study Under the FDA's Approved Dual Concurrent Protocol
March 22, 2021
Premas Biotech and Oramed Announce Oral COVID-19 Vaccine Candidate That Produces Antibodies After a Single Dose
March 18, 2021
Oramed Forms a Joint Venture, Oravax Medical Inc., for the Development of Novel Oral COVID-19 Vaccines
March 18, 2021
Oramed Reaches 25% Randomization in World's First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol
March 15, 2021
Oramed to Present at H.C. Wainwright Global Life Sciences Conference 2021
March 3, 2021
Oramed Issues Letter to Shareholders
January 26, 2021
Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study
January 20, 2021
Oramed to Present at H.C. Wainwright BioConnect 2021 Conference
January 6, 2021
Oramed Reports Positive First in Human Data from Oral Leptin Study
December 22, 2020
Oramed Initiates Phase 2 NASH Trial of Oral Insulin
December 1, 2020
Oramed Initiates Phase 3 Trial of Oral Insulin
November 23, 2020
Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar "Oral Delivery of Therapeutic Proteins - Oramed Story" on November 18, 2020
November 11, 2020
Oramed to Present at H.C. Wainwright 6th Annual Israel Conference
November 9, 2020
Oramed to Present Phase 2b Oral Insulin Data at American Association of Pharmaceutical Scientists 2020 PharmSci 360 Conference
October 27, 2020
Oramed CEO Nadav Kidron & Premas Biotech to Host Webinar "The Journey of Oral Insulin: Oramed Story" on Wednesday October 28, 2020
October 26, 2020
Oramed Issues Shareholder Update on Pivotal Phase 3 Oral Insulin Studies: Protocols Submitted to FDA
October 15, 2020
Oramed Pharmaceuticals to Present at the European Association for the Study of Diabetes (EASD) Annual Meeting
September 20, 2020
Oramed's Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients
September 14, 2020